FDA grants priority review to TAR-200, which demonstrated an 82% complete response in high-risk bladder cancer unresponsive ...

ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics announced today OncoPrism for colorectal, breast, bladder, and kidney cancer. This announcement follows recent Medicare coverage of the OncoPrism ...

BCG therapy—the gold standard treatment for non-muscle invasive bladder cancer (NMIBC), where the cancer has not penetrated the muscle layer—is one of the earliest forms of cancer immunotherapy.